Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Altimmune Inc (DE:3G0)
FRANKFURT:3G0
Holding DE:3G0?
Track your performance easily
3G0 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€1.97 - €13.70
Previous Close€6.25
Volume0.00
Average Volume (3M)489.00
Market Cap
€446.60M
Enterprise Value€298.15M
Total Cash (Recent Filing)$164.91M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.45
Next Earnings
Nov 05, 2024EPS Estimate
-€0.32Last Dividend Ex-Date
Feb 06, 2017Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding71,070,951
10 Day Avg. Volume244
30 Day Avg. Volume489
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)2.91
Price to Sales (P/S)1237.23
Price to Cash Flow (P/CF)-7.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue728.98
Enterprise Value/Gross Profit699.89
Enterprise Value/Ebitda-3.03
Forecast
1Y Price Target
€19.03Price Target Upside204.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Altimmune News
Bulls Say, Bears Say
Bulls Say
EfficacyThe new body composition analysis shows pemvi preserves lean mass more in older patients that need this benefit most and a preferential loss of visceral adipose tissue that may reduce the risk of metabolic syndrome, cardiovascular disease, and certain cancers.
Market PotentialManagement noted plans to pursue up to three additional indications to optimally pursue pemvi's glucagon-mediated efficacy.
Safety ProfileThere were no surprises to pemvidutide's safety and tolerability profile, suggesting that the ongoing Ph. IIb IMPACT MASH 24-week liver biopsy study might further reduce investor concerns.
Bears Say
Clinical TrialsLimited safety data from the NASH trial note that survodutide appears to be harder to tolerate than pemvidutide, which could affect its future success.
Drug TolerabilitySurvodutide showed one of the worst tolerability profiles for a GLP-based candidate, raising concerns about its market acceptance.
Product DevelopmentThe company is discontinuing development of hepatitis B candidate HepTCell, eliminating a potential growth avenue.
---
3G0 FAQ
What was Altimmune Inc’s price range in the past 12 months?
Altimmune Inc lowest stock price was €1.97 and its highest was €13.70 in the past 12 months.
What is Altimmune Inc’s market cap?
Currently, no data Available
When is Altimmune Inc’s upcoming earnings report date?
Altimmune Inc’s upcoming earnings report date is Nov 05, 2024 which is in 40 days.
How were Altimmune Inc’s earnings last quarter?
Altimmune Inc released its earnings results on Aug 08, 2024. The company reported -€0.314 earnings per share for the quarter, missing the consensus estimate of -€0.313 by >-€0.001.
Is Altimmune Inc overvalued?
According to Wall Street analysts Altimmune Inc’s price is currently Undervalued.
Does Altimmune Inc pay dividends?
Altimmune Inc pays a Notavailable dividend of €780.27 which represents an annual dividend yield of N/A. See more information on Altimmune Inc dividends here
What is Altimmune Inc’s EPS estimate?
Altimmune Inc’s EPS estimate is -€0.32.
How many shares outstanding does Altimmune Inc have?
Altimmune Inc has 71,070,950 shares outstanding.
What happened to Altimmune Inc’s price movement after its last earnings report?
Altimmune Inc reported an EPS of -€0.314 in its last earnings report, missing expectations of -€0.313. Following the earnings report the stock price went down -3.462%.
Which hedge fund is a major shareholder of Altimmune Inc?
Among the largest hedge funds holding Altimmune Inc’s share is Ardsley Advisory Partners. It holds Altimmune Inc’s shares valued at 2M.
---
Altimmune Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€19.03 (204.60% Upside)
€19.03 (204.60% Upside)
Blogger Sentiment
Bullish
DE:3G0 Sentiment 97%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $110.5K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
178.88%
12-Months-Change
Fundamentals
Return on Equity
-63.29%
Trailing 12-Months
Asset Growth
-5.44%
Trailing 12-Months
Company Description
Altimmune Inc
The Group is development stage company which intend to acquire an operating business, through a merger, capital stock exchange, asset acquisition or other similar business combination. The Group does not have any activities.
---
3G0 Earnings Call
Q2 2024
0:00 / 0:00
---
3G0 Stock 12 Month Forecast
Average Price Target
€19.03
▲(204.60% Upside)
Technical Analysis
Best Analysts Covering 3G0
1 Year
1 Year Success Rate
17/34 ratings generated profit
1 Year Average Return
+8.33%
reiterated a buy rating 2 months ago
Copying Mayank Mamtani's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +8.33% per trade.
---